1. Home
  2. CGEM vs UVSP Comparison

CGEM vs UVSP Comparison

Compare CGEM & UVSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$19.62

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

UVSP

Univest Financial Corporation

N/A

Current Price

$43.06

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CGEM
UVSP
Founded
2016
1876
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
CGEM
UVSP
Price
$19.62
$43.06
Analyst Decision
Strong Buy
Hold
Analyst Count
8
3
Target Price
$30.13
$36.67
AVG Volume (30 Days)
528.4K
260.9K
Earning Date
05-11-2026
04-22-2026
Dividend Yield
N/A
2.44%
EPS Growth
N/A
21.32
EPS
N/A
1.78
Revenue
N/A
$328,056,000.00
Revenue This Year
N/A
$11.65
Revenue Next Year
$5.20
$4.77
P/E Ratio
N/A
$24.12
Revenue Growth
N/A
9.64
52 Week Low
$5.68
$28.04
52 Week High
$19.94
$45.46

Technical Indicators

Market Signals
Indicator
CGEM
UVSP
Relative Strength Index (RSI) 66.45 44.97
Support Level $11.87 $42.55
Resistance Level N/A $43.26
Average True Range (ATR) 0.99 0.80
MACD 0.20 -0.30
Stochastic Oscillator 93.11 26.95

Price Performance

Historical Comparison
CGEM
UVSP

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About UVSP Univest Financial Corporation

Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.

Share on Social Networks: